SAP LeapFrogs Novo Nordisk to become the most valuable company in Europe

Unlock the editor’s digestion free

FT editor Roula Khalaf, chooses his favorite stories in this weekly newsletter.

The program giant SAP, Danish Medicinal Nordisk Nordisk Nordisk, the most valuable company in Germany, he estimated that it will be the last stage for Germany’s latest stage.

Leak On Monday, Shares lifted more than 312 billion euros on Monday, lifting more than 312 billion euros on Monday, only Novo Nordisk decreased.

SAP shares have risen more than 40 percent in the last year, because investors welcomed the change of clouds of business clouds, and the group waves the wave of artificial intelligence. Helped make a profit for the handle Rally in Frankfurt’s Blue-Chip Dax Index This has been ahead of the majority of the world’s major stock markets.

Novo Nordisk has lost half of the market value since last summer, because it persuades investors that Blockbuster GLP-1 has a great pursuit of obesity medications.

“Novo has been a hot stock in the past, but now that we see that the hype is the descent. SAP, German capital benefits from flowers,” said Barclays.

Last year SAP Dutch semiconductor equipment manufacturer OSM was changedL As the largest technology company in Europe.

SAP, located in Walldorf, Germany, is now a larger part of the German index from the country’s historical automotive sector, which is now in Volkswagen and Mercedes-Benz.

On the HEAT’S WEBSITE DAX, Deutsche Börse’nin 15 percent of the 40 percent of the cap, which was asked to present a new unprecedented version of the index, broke a few percent caps.

In 1972, the SAP, built by five former IBM employees, made progress in recent years to sell cloud service contracts, a more predicted and profitable program to sell.

Analysts are expected to grow 29 percent this year, and the total income is projected to increase by 13 percent to 38.5 billion euros.

Analysts also emphasized the potential of a new product that allows customer information to connect information with third-party data and to analyze them through AI-powered agents.

Although the company’s shares are all the time of last month, about 10 percent of the high level, the competitors fell even more for the position of the most valuable company.

In the last two years, the French Luxury Group Lvmh, the highest point in Europe, has published a second set this month worse than expected Test results for Cagrisma, which is a potential heir treatment in Ozempic and Wegovy.

Novo’s vague product pipeline has made a success story that sees the available sales Obesity drugs More than 50 percent last year.